Introduction

Olivier Delattre: Historical Background and Challenges Ahead

Chromatin Remodeling & Epigenetics – Towards Therapeutic Interventions

Charles Roberts: SMARCB1-deficient cancers: mechanisms and vulnerabilities
Matthieu Gérard: SMARCB1 and BRG1 generate subnucleosomes that expand transcription factor binding and function at enhancers
Irwin Davidson: BRG1 in oncogenesis, the example of melanoma
Cigall Kadoch: Structure and function of mSWI/SNF ATP-dependent chromatin remodeling complexes in SMARCB1-deficient cancers
Nada Jabado: PRC1, PRC2, BAF and COMPASS complexes: it takes more than 2 to tango in pediatric high grade brain tumors

From Cell-of-Origin to Transformed Cells

Steve Baylin: Roles for abnormal DNA methylation and chromatin remodeling in the origins of human cancer – from cell of origin to transformed cells
Sam Behjati: Phylogenetic approaches to finding the cell of origin of rhabdoid tumors
Jarno Drost: Patient-specific epigenetic reprogramming drives malignant rhabdoid tumorigenesis
Franck Bourdeaut: Cell-of-origin – what mouse models can teach us

Constellation of SMARCB1/A4-deficient Tumors – Overlaps and Specificities

William Foulkes: SMARCA4 – updates on associated phenotypes, plausible treatment targets and available resources
Sophie Postel-Vinay: Epithelioid sarcoma: exploring tumor heterogeneity
Thomas Grünewald: Functional and translational genomics of Epithelioid sarcoma
Charles Keller: Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology
Martin Hasselblatt: Rare SMARCB1-deficient tumors of the CNS: Misfits or potential clues to a better understanding of rhabdoid tumor biology?
Gabriel Malouf: Role of SMARCB1 alterations in renal medullary carcinomas
Josh Sommer: Accelerating rare cancer research — the Chordoma Foundation experience

Models, Stratification & Perspectives in Therapeutic Targetting

Annie Huang: ATRTs sub-grouping – sufficient for therapeutic stratification?
Marcel Kool: Single cell transcriptional profiling of ATRTs
Paul Huang: The proteomic landscape of SMARCB1-deficient cancers
Dan Williamson: Subgroup/location-independent prognostic signatures and their correlates in Malignant Rhabdoid Tumors
Mrinal Gounder: Clinical Trials in SMARCB1 altered cancers – Past and Future Directions
Alex Kentsis: Overcoming clinical resistance to EZH2 inhibition of rhabdoid tumors using rational epigenetic combination therapy
Susan Chi: EZH2 inhibition: the long journey of pediatric drug development
Michael Fruehwald: Risk stratification in rhabdoid tumors – the need for novel markers AND therapies
Ulrich Schüller: Comparative analysis of matched primary and relapsing atypical teratoid/rhabdoid tumors (AT/RT)

The Tumor Cell in its “Omic” & Microenvironment Contexts

Emmanuel Donnadieu: Imaging of failure and success of CAR T-cells in human tumors
Daniel de Carvalho: Viral mimicry response to EZH2 inhibition in SMARCB1-deficient cancers
Eliane Piaggio: Immunotherapy of RT: a translational approach
Josh Waterfall: Transcriptional dysregulation as a source of tumor specific antigens
David Sourdive: Smart cells : an industrial perspective in adoptive cancer immunotherapy

Breakout Brainstorming Sessions